We take pride in our Corporate Social Responsibility (CSR) activities. These are activities that transcend short-term focus on profits and address greater societal need.
SARS-COV2 (COVID19) protein structure - FDA active compound simulation
We are simulating 1213+ FDA approved active compounds against published SARS-COV2 (COVID-19) protein structures to see if an existing compound can affect viral protein assembly and/or activity. The list or proteins we are looking at are provided below. We are using three separate super-computing facilities and already have results for proteins 6w4b (nsp9 replicase), 6lxt (part of S2 sub-domain) and three others. Please contact us if you would like to request these results. MGHPCC recently wrote about this work here. As of October 2020 we have access to over 800k detailed de-identified patient records to further its COVID-19 research.